Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000 cr nutraceuticals market
Mamaearth-parent Honasa Consumer acquires 58% stake in Fluence Pharma at ₹135 crore enterprise value, with the remaining 42% to be picked up in two tranches over 5-7 years. The deal launches new subsidiary Honasa Health and marks entry into India's ₹16,000 crore nutraceuticals segment growing at 11%, leveraging Fluence's 3,000-dermatologist network.
What happened
Honasa Consumer acquires 58% of nutraceuticals firm Fluence Pharma at ₹135 crore EV, with remaining 42% over 5-7 years. Marks Mamaearth-parent's entry into
Key facts
- 58% stake
- ₹135 crore EV
- 42% in 2 tranches over 5-7 years
- share ₹420
- nutraceuticals market ₹16,000 crore
- 11% growth
- 3,000 dermatologists
- FY26 net profit ₹200 crore vs ₹72.6 crore
- revenue ₹2,391 crore +15% YoY
Why this matters
The staggered 58/42 structure with a 5-7 year tail is the template to watch—Honasa locks control today, defers dilution, and ties founder payout to performance, a playbook replicable for any consumer platform bolting on regulated/clinician-led adjacencies.